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Abstract
Background: Angelman syndrome (AS) is a neurodevelopmental disorder that is caused by maternal genetic
deficiency of a gene that encodes E6-AP ubiquitin-protein ligase (gene symbol UBE3A) mapping to chromosome
15q11-q13. AS leads to stiff and jerky gait, excess laughter, seizures, and severe intellectual disability. In some parts
of the brain, the paternally inherited UBE3A gene is subject to genomic imprinting by the action of the UBE3A-
antisense transcript (UBE3A-ATS) on the paternally inherited allele. Consequently, only the maternally inherited
UBE3A gene is expressed in mature neurons. AS occurs due to deletions of the maternal 15q11 − 13 region,
paternal uniparental disomy (UPD), imprinting center defects, mutations in the maternal UBE3A gene, or other
unknown genetic malfunctions that result in a silenced maternal UBE3A gene in the specific imprinted regions of
the brain.
Results: A potential treatment strategy for AS is to increase methylation of UBE3A-ATS to promote expression of the
paternal UBE3A gene and thus ameliorate the clinical phenotypes of AS. We treated two sets of male identical twins
with class I deletions with a 1 year treatment trial of either betaine and folic acid versus placebo. We found no
statistically significant changes in the clinical parameters tested at the end of the 1 year trial, nor did we find any
significant adverse events.
Conclusions: This study tested the hypothesis that by increasing the methylation of the UBE3A-antisense transcript
in Angelman syndrome to promote expression of the silenced paternal UBE3A gene we may ameliorate the clinical
phenotypes of AS. We treated two sets of identical twins with placebo versus betaine and folic acid. Although this
study represented a novel approach to treating Angelman syndrome, the differences in the developmental testing
results was not significant. This paper also discusses the value of monozygotic twin studies in minimizing
confounding variables and its utility in conducting small treatment studies.
Trial registration: NCT00348933. Registered 6 July 2006.
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Introduction
Angelman syndrome (AS), first described by Harry
Angelman in 1965, is a neurodevelopmental disorder
that is characterized by severe congenital intellectual dis-
abilities, ataxia, unusual facial appearance, and a happy/
sociable disposition) [1]. AS is caused by de novo mater-
nal deletions of chromosome 15q11-q13 (70–80%), in-
tragenic mutations in the maternally inherited UBE3A
within chromosome15q11-q13 (10–20%), paternal uni-
parental disomy (UPD) for chromosome 15q11-q13 (3–
5%), or imprinting defects within chromosome 15q11-
q13 that alter the expression of maternally inherited
UBE3A (3–5%) [2, 3]. UBE3A is expressed from both the
paternal and maternal chromosome in somatic tissues
and in many parts of the brain; however, only the mater-
nally inherited gene is expressed in mature neurons [4].
The UBE3A antisense transcript (UBE3A-ATS) is pre-
sumed to be responsible for silencing the paternal
UBE3A expression in these cells. It is hypothesized that
increased methylation of UBE3A-ATS may increase ex-
pression of the paternally inherited UBE3A gene and
ameliorate the phenotypes in Angelman syndrome [5].
The use of methyl donors in the diet were hypothesized
to promote such an effect. Our treatment rationale was
to increase global methylation levels in the brain to pro-
mote gene expression from the silent UBE3A paternal
allele through a one-year treatment trial of betaine and
folic acid [6, 7]. This case report limits biological and
environmental variability by studying a small sample of
two sets of identical twins. In a larger study, confound-
ing variables may affect the results.
Methods
Experimental subjects
Two sets of identical twin male siblings were studied
under an Institutional Review Board-approved protocol
at Boston Children’s Hospital (Committee on Clinical
Investigation) (twins A and B) and Rady Children’s Hos-
pital, San Diego (UC San Diego Pediatric Institutional
Review Board) (twins C and D). Written informed con-
sent was obtained from parents before enrollment. Re-
cruitment followed the standards of the Declaration of
Helsinki. Inclusion criteria for the study included labora-
tory confirmation of diagnosis for common deletion,
UPD, imprinting defect, or UBE3A mutation. Patients
with a clinical diagnosis of AS but no identifiable mo-
lecular genetic abnormality were not be eligible to enroll.
Patients who were not clinically stable were excluded
from the study. All racial/ethnic were eligible for the
study. All patients had Fluorescent in situ hybridization
(FISH) studies which showed deletions on chromosome
15, and DNA methylation studies were diagnostic of AS.
Additional studies performed by MLPA to determine
deletion size indicated that all subjects had a larger class
1 deletion.
Clinical protocol
The two sets of identical twins were studied in a
placebo-controlled double-blind treatment trial of beta-
ine and folic acid treatment. Twins A, C and D were
randomized independently using a centralized method
so their assignment was random. Twin A was assigned
placebo randomly and twin B was assigned betaine and
folic acid. Twin C was assigned placebo and twin D was
assigned betaine and folic acid. Twins A and B were
enrolled at 8 years and 5months respectively, twin C at
5 years and 8months and twin D when 7 years old. All
twins completed the study.
Evaluation
At baseline, 6, and 12months the patients underwent clin-
ical evaluations from a clinical geneticist, neurologist, and
psychologist, developmental and laboratory evaluations,
and every 3months the parents were asked to complete a
questionnaire. The parent questionnaire monitored the
child’s overall behavior, i.e. feeding difficulties, oral sensi-
tivity, sleep, drooling, toilet training, tremoring sitting,
standing, nonverbal communication, hypermotoric behav-
ior, and attention span.
The developmental evaluations included a total of four
tests. Bayley Scales of Infant Development, Second Edition
(BSID-II) [8] and the Vineland Adaptive Behavior Scales –
Interview Edition [9] were used to assess cognitive and
motor skills. The Preschool Language Scale, Third Edition
(PLS-III) [10] and the MacArthur Developmental Inven-
tory [11] were used to assess communication skills. ADOS
and ADI testing was not performed in one set of twins
only. Laboratory testing included CBC, urinalysis, folate
levels at Quest Diagnostics in Cambridge, MA, and
plasma betaine and amino acid levels at Baylor College of
Medicine.
Case report
Twins A and B
Twin A and B were idenitical monoamniotic twins born
to a 24-year-old G3 P2 mother and a 31-year-old father.
The pregnancy was complicated by twin gestation diag-
nosed at 7 weeks, and gestational diabetes in the last
month of pregnancy, which was controlled by diet. Deliv-
ery by repeat Caesarean section at 35 ½weeks of second-
ary to prior uterine surgery for an ectopic pregnancy.
Twin A
The neonatal period was unremarkable. At two and a
half months he had an incarcerated left inguinal hernia
that was repaired surgically. He has had a history of clin-
ical seizures since the age of 15 months controlled by
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medication including topiramate, clonazepam, and so-
dium valproate.
On examination at 8.4 years his height was 127.3 cm
(50%), weight 25.9 kg (50%), and head circumference
52.5 cm (50%). Physical findings included brachycephaly,
mid-facial retrusion, prognathism, macrostomia, wide-
spaced teeth, tongue thrusting and strabismus. General
examination of heart, lungs, and abdomen was unre-
markable. On neurological exam, cranial nerves were
grossly intact. His motor examination was notable for
truncal hypotonia and increased tone in all extremities.
He had jerky movements and a wide-based gait with his
arms held in flexion when walking. His EEG at age 8
years was abnormal with widespread delta slowing max-
imal posteriorly at the fully alert state but dominant
frontally in addition to delta, notched delta blunted spike
waves or frank spike waves were seen of which one was
associated with a clinical event (grunting).
Twin B
Twin B had mild respiratory distress at birth and was
admitted to the Neonatal Intensive Care Unit for 10 days
for antibiotic therapy for pneumonia. He began to have
seizures at 15 months of age, during which he would
tighten his jaw, make growling noises, and have rhyth-
mic tremors. His seizures were controlled by medication
EEG obtained at 8 years was suggestive of an active seiz-
ure disorder, very characteristic of Angelman syndrome
with widespread posterior discharges consisting of delta,
notched delta and spike waves. On examination at 8 y.
and 5 mo., his height was 128.2 cm (50%), weight 26 kg
(50%) and head circumference 53 cm (50-75%). Cranio-
facial features were identical to his twin. Unlike his twin,
he aexhibited mild scoliosis. Both twins were diagnosed
with Angelman syndrome at 16 months of age through
FISH testing with probes from D15S11 and GABRB3
that showed a typical Angelman syndrome Class I dele-
tion at chromosome 15. DNA methylation studies were
conducted and concluded to be diagnostic of AS.
Twins C and D
Twins C and D were born to a 29 year old G2 P0 mother
and 34 year old father. The pregnancy was naturally con-
ceived and a routine ultrasound at 16 weeks gestation
revealed monoamniotic monochorionic twins. There
were no exposures during the pregnancy. An ultrasound
disclosed no problems. The pregnancy was complicated
by preterm contractions beginning at 29 weeks, treated
with bedrest and terbutaline, and HELLP syndrome,
treated with MgSO4. At 34 weeks gestation, rupture of
membranes occurred, and induction of labor was under-
taken. Twin D was born vaginally, but twin C was
delivered by emergency caesarean section due to cord
prolapse.
Both twins had severe muscle hypotonia that persisted
beyond a year of age and were diagnosed with Prader-
Willi syndrome based on FISH at 13 months. Breast
feeding was not successful due to a weak suck and they
were fed breast milk in a bottle with a preemie nipple
for 1 month and then transitioned to formula. Their
coloring was lighter than expected for the family. At 2
years of age, the diagnosis was changed to Angelman
syndrome based on DNA methylation results. Twin C
was examined at 5 years and 8months and twin D was
examined at 7 years of age. Their chromosome 15q11-
q13 deletion associated with Angelman syndrome was
characterized as a Class I deletion.
Twin C
Twin C weighed 2.15 kg, measured 47 cm, and had Apgar
scores of 4 and 7. He stayed for 9 days in the Neonatal In-
tensive Care Unit for temperature regulation and feeding
issues. He had febrile seizures in association with a re-
spiratory infection at age 4months, and non-febrile con-
vulsions began at age 28months. He had several episodes
of status epilepticus and failed management with 6 anti-
epileptic medications. Severe failure to thrive necessitated
percutaneous gastrostomy tube placement at 3 years of
age. When evaluated at age 5 years 8months, he weighed
16 kg (12%), measured 112 cm (70%), and had a head cir-
cumference of 49 cm (75%). He had microbrachycephaly
with an occipital ridge, exotropia, midface retrusion, prog-
nathism, and macrostomia with widely spaced teeth. He
had a moderate rightward thoracic and leftward lumbar
scoliosis and pronated ankles. He had generalized muscle
hypotonia.
Twin D
Twin D weighed 2.13 kg, measured 47 cm, and had
Apgar scores of 4 and 7. He was gavage fed for 3 days
Table 1 Summary of clinical features in twin pairs
Twin Gestation age Birthweight Apgar Scores
(1,5 min)
Deletion Size ADOS Seizure Onset Medications
A 35.5 weeks 2.75 kg 8, 9 Class 1 Not tested 15 months Topamax, Clonazepam, Valproate
B 35.5 weeks 2.47 kg 3, 6 Class 1 Not tested 15 months Topamax, Clonazepam, Valproate
C 34 weeks 2.15 kg 4, 7 Class 1 Autism 4 months Miralax, Lamictal, Zonagran, Melatonin
D 34 weeks 2.13 kg 4, 7 Class 1 Autism 4 months Miralax, Lamictal, Zonagran, Klonopin, Melatonin
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Table 2 Developmental Testing Scores at baseline, 6 months and at 12 months
Variables (Raw Scores) at 0, 6 and 12 months TWIN 0 6 12 cScore 6-0 cScore 12-6 c Total Score
Bayley Mental Aa 76 83 90 7 7 14
Bb 77 78 78 1 0 1
Ca 70 77 78 7 1 8
Db 73 73 76 0 3 3
Bayley Motor A 66 67 74 1 7 8
B 66 67 73 1 6 7
C 38 41 44 2 3 5
D 51 50 47 -1 −3 −4
Preschool Language Auditory Comprehension A 8 9 9 1 0 1
B 8 8 9 0 1 1
C 5 7 6 2 −1 1
D 5 5 7 0 2 2
Preschool Language Expressive Communication A 6 9 9 3 0 3
B 5 9 8 4 −1 3
C 6 6 6 0 0 0
D 4 3 3 −1 0 −1
Preschool Language Composite A 14 18 18 4 0 4
B 13 17 17 4 0 4
C 11 13 12 2 −1 1
D 9 8 10 −1 2 1
*Vineland Communication A 24 24 26 0 2 2
B 24 23 25 −1 2 1
C 12 14 16 2 2 4
D 14 15 14 1 −1 0
*Vineland Daily Living A 31 31 35 0 4 4
B 29 27 33 −2 6 4
C 7 6 6 −1 0 −1
D 8 9 8 1 − 1 0
*Vineland Socialization A 29 33 33 4 0 4
B 27 29 33 2 4 6
C 25 30 30 5 0 5
D 23 26 17 3 −9 −6
*Vineland Adaptive Behavior Composite A 164 117 131 −47 14 −33
B 80 105 127 25 22 47
C 139 131 106 −8 −25 −33
D 145 136 123 −9 −13 − 22
*Vineland Adaptive Behavior Composite (standard scores) A 29 28 27 −1 −1 −2
B 29 – 26 – – −3
C 32 30 32 −2 2 0
D 33 42 28 9 −14 −5
MacArthur Communicative Developmental Inventory
Phrases understood
A 25 25 16 0 −9 −9
B 19 22 15 3 −7 −4
C 2 0 0 −2 0 −2
D 0 0 2 0 2 2
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and discharged home at 9 days. Exotropia and sleep
disturbance were noted from infancy. Food refusal and
severe failure to thrive necessitated percutaneous gas-
trostomy tube placement at 3 years of age. There were
multiple episodes of otitis media and pneumonia, the
latter presumed due to aspiration. Gagging and gastro-
esophageal reflux disease resulted in many episodes of
emesis per day.
Seizures with fever began at 4 months, and afebrile sei-
zures started at 28 months of age. Nearly all develop-
mental skills were lost until seizure control was achieved
approximately several months later, following which
skills were regained slowly. On examination at 7 years of
age, he weighed 19.5 kg (10%), measured 119.3 cm (30%)
and had a head circumference of 49.4 cm (50%). He had
alternating exotropia, midface retrusion, prognathism,
widely spaced teeth, and mild rightward thoracic and
leftward lumbar scoliosis. His truncal tone was low, and
there was high extensor tone in all extremities.
Developmental testing and results
Developmental testing was performed by psychologists
at Boston Children’s Hospital (twins A and B) and Rady
Children’s Hospital San Diego (twins C and D). Table 1
summarizes features of all four twins. Table 2 presents
raw scores at baseline, 6 months and 12 months after
study enrollment (treatment or placebo). For the most
part, raw scores are reported, since performance was far
below the designated basal score in the norm tables of
the manuals. We also present the standard score for the
Vineland Adaptive Behavior Composite, which has a
normative mean of 100 ± 15.
This case study did not demonstrate significant develop-
mental differences between twin A (treated with placebo)
and twin B (treated with betaine and folic acid) nor be-
tween twin C (treated with placebo) and twin D (treated
with betaine and folic acid). There was no statistically sig-
nificant difference between the two sets of twins. Table 2
delineates scores from all developmental testing over a 12-
month period. Figure 1 summarizes the total score differ-
ence in each test for twins A, B, C, and D. All twins were
below the normative mean (100 ± 15) of the Vineland
Adaptive Behavior Composite, perhaps attributed to their
large deletion classes (Table 2). Twins A and B exhibited
higher Bayley Motor, Vineland Communication, Vineland
Daily Living, and MacArthur Communicative Develop-
mental Inventory Phrases Understood scores than twins C
and D over a 12-month period. All twins exhibited similar
scores with no significant improvement in Bayley Mental,
Preschool Language Auditory Comprehension, Preschool
Language Expressive Communication, Preschool Lan-
guage Composite, Vineland Socialization, and Vineland
Adaptive Behavior Composite. However, between the two
sets of twins, twins C and D improved in MacArthur
Communicative Developmental Inventory Vocabulary
Comprehension while twins A and B worsened over a 12-
month period (Fig. 1). There was no significant differences
in the serum levels of betaine in the two groups.
Discussion
Angelman syndrome is a neurodevelopmental disorder
with severe mental impairments, neurological impairments,
neurological defects, seizures, sleep disturbances, and lack
of sleep among its major clinical manifestations [12, 13]. In
hopes of mitigating these phenotypic characteristics, we
treated a set of identical twins with either placebo or folic
acid and betaine to increase methylation of UBE3A-ATS
and hopefully increase expression of the paternally inher-
ited UBE3A protein. Betaine is known to cross the blood
brain barrier and animal studies also indicate that hippo-
campal slices actively accumulate betaine in a time, dose
and osmolality dependent manner, resulting in peak intra-
cellular concentrations four times extracellular concentra-
tions within 8 h. Betaine thus has the potential to modulate
neuronal excitability and induce the hippocampus to medi-
ate learning and memory and promote cognition [14].
Table 2 Developmental Testing Scores at baseline, 6 months and at 12 months (Continued)
Variables (Raw Scores) at 0, 6 and 12 months TWIN 0 6 12 cScore 6-0 cScore 12-6 c Total Score
MacArthur Communicative Developmental Inventory
Vocabulary comprehension
A 1 3 0 2 −3 −1
B 1 2 0 1 −2 −1
C 1 0 5 − 1 5 4
D 3 2 8 −1 6 5
MacArthur Communicative Developmental Inventory production A 0 0 1 0 1 1
B 0 2 0 2 −2 0
C 1 0 1 −1 1 0
D 0 0 0 0 0 0
* Vineland did not include the motor skills portion because the twins were over age 6 years
The labels a for placebo, and the label b for drug (betaine and folic acid) treatment applies to all the testing groups. c refers to differences in the scores between
baseline, 6 months and 12 months
P-values calculated through t-test were not statistically significant
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Fig. 1 Graphs of total score differences in Bayley, Preschool Language, Vineland, and MacArthur tests across twin A, B, C, and D. *P-values
calculated through Student’s t-test were not statistically significant (all p-values>0.05)
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No consistent pattern of improvement however was
seen in twins B or D, who received treatment, in com-
parison to twins A and C, who did not. These findings
complement the studies of Peters et al. [7], in which
betaine and folic acid treatment in 48 AS patients
showed no statistically significant changes in the clinical
phenotype. They found that children who were on medi-
cations and did not have a diagnosis of co-morbid aut-
ism showed an upward trend in their development;
however, differences were not statistically significant [7].
The four patients in this case study were included in the
larger study of Peters et al. [7]; however, we provide
more details on the two sets of identical twins because
of the power of monozygotic twin analysis.
Though the treatment had no statistical effect on any
of these subjects via student’s t-test (all p-values> 0.05),
these two sets of twins with Angelman syndrome are es-
pecially informative because both sets are matched for
similarity for the larger deletion size (Class I), including
scores and phenotype between twins and between sets of
twins. The outcome measures used in this trial were
designed for the general population and may not be ap-
propriate for picking up incremental developmental
changes in people with Angelman syndrome, as scores
were almost at the floor of each of the developmental as-
says. However, scores for all four subjects on the devel-
opmental tests described here were remarkably similar
and stable over time. All four of these subjects scored
comparatively low compared to the remainder of the
subject population, which may be due to their larger
deletion size, or may be due to other variables related to
multiple birth, such as prematurity. Previous studies
have shown that patients with Class I deletion are at
higher risk of autism than others with Angelman syn-
drome, and those subjects in the trial without autism
showed a trend toward a beneficial effect of the treat-
ment [7]. Twins C and D tested positive for autism via
the Autism Diagnostic Observation Schedule [15]. Un-
fortunately, twins A and B were not tested for autism
but clinically did not exhibit features of autism.
Monozygotic (MZ) twin studies in disease and epigen-
etic studies are valuable because there is a significant
reduction of confounding variables and a smaller cohort
that can provide useful data. MZ twin studies control for
the effects of age, sex and genetic factors, which facili-
tates the assessment of treatment effects [16]. This study
design has been used by many other researchers in the
past. Oberfield [17] treated one set of identical twins di-
agnosed with nephropathic cystinosis with ascorbic acid
versus placebo. Hunter [18] conducted a longitudinal,
placebo-controlled, double blind trial of vitamin D sup-
plements on identical female twins and concluded that
they did not find any significant prevention of osteopor-
osis. Ferraresi [19] employed a placebo-controlled Light-
Emitting Diode Therapy on one pair of identical twins
and found significantly decreased levels of interleukin 1β
(markers of inflammation) and myostatin (markers of
muscle atrophy) in the treated twin. Ring [20] also
treated one set of identical twins suffering from severe
atopic eczema with grass pollen and saline versus pla-
cebo and found statistically significant improvement in
clinical phenotype in the treated twin. In these MZ twin
studies, the incorporation of MZ twins as identical con-
trols led to clear and dependable data on the effect of
novel treatments on very small sets of patients. Simi-
larly in our study, data from the MZ twins minimized
confounding variables, such as age, gender, cultural, en-
vironmental, or genetic factors, and allowed for reliable
conclusions. We however did not find significant im-
provements with the betaine and folic acid treatment,
nor did we find negative effects of the treatment in the
treated twins.
Conclusions
Betaine and folic acid treatment was shown to have no
statistically significant effect on treated twins compared
to control. The nature of this study as a monozygotic
twin investigation adds validity to the controllability and
consistency of the results, as many confounding factors
have been accounted for.
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